Daniel S. Lorrain
Chief Scientific Officer at Contineum Therapeutics, Inc. (CTNM)
Purchase track record
Not enough history. Based on 0 purchases with a full 90 days of price history.
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| Jul 10SEC | CTNMContineum Therapeutics, Inc. | Sell Plan | 1,015135,202 held (−1%) | $16.00 | $16K | -16.4% |
| Jul 10SEC | CTNMContineum Therapeutics, Inc. | Sell Plan | 25135,202 held (−0%) | $16.00 | $400 | -16.4% |
| Jul 2SEC | CTNMContineum Therapeutics, Inc. | Sell Plan | 28,826139,372 held (−17%) | $16.04 | $462K | -16.6% |
| Jul 2SEC | CTNMContineum Therapeutics, Inc. | Sell Plan | 5,852137,703 held (−4%) | $15.67 | $92K | -14.6% |
| Jul 2SEC | CTNMContineum Therapeutics, Inc. | Sell Plan | 2,501135,202 held (−2%) | $16.24 | $41K | -17.6% |
| Jun 1SEC | CTNMContineum Therapeutics, Inc. | Sell Plan | 4,170139,372 held (−3%) | $13.16 | $55K | +1.7% |
| May 1SEC | CTNMContineum Therapeutics, Inc. | Sell Plan | 3,870143,842 held (−3%) | $13.06 | $51K | +2.5% |
| May 1SEC | CTNMContineum Therapeutics, Inc. | Sell Plan | 300143,542 held (−0%) | $13.84 | $4K | -3.3% |
| Apr 6SEC | CTNMContineum Therapeutics, Inc. | Sell Plan | 4,170147,712 held (−3%) | $13.43 | $56K | -0.4% |
| Mar 2SEC | CTNMContineum Therapeutics, Inc. | Sell Plan | 4,170151,882 held (−3%) | $15.01 | $63K | -10.9% |
| Feb 26SEC | CTNMContineum Therapeutics, Inc. | Sell Plan | 4,300156,052 held (−3%) | $16.03 | $69K | -16.5% |
| Feb 26SEC | CTNMContineum Therapeutics, Inc. | Sell Plan | 3,824156,052 held (−2%) | $16.01 | $61K | -16.4% |
| Feb 20SEC | CTNMContineum Therapeutics, Inc. | Sell Plan | 100156,052 held (−0%) | $16.00 | $2K | -16.4% |
| Feb 13SEC | CTNMContineum Therapeutics, Inc. | Sell Plan | 400156,052 held (−0%) | $16.00 | $6K | -16.4% |
| Feb 5SEC | CTNMContineum Therapeutics, Inc. | Sell Plan | 3,000157,222 held (−2%) | $14.82 | $44K | -9.7% |
| Feb 5SEC | CTNMContineum Therapeutics, Inc. | Sell Plan | 1,170156,052 held (−1%) | $15.25 | $18K | -12.3% |
| Jan 6SEC | CTNMContineum Therapeutics, Inc. | Sell Plan | 3,670160,722 held (−2%) | $10.35 | $38K | +29.3% |
| Jan 6SEC | CTNMContineum Therapeutics, Inc. | Sell Plan | 500160,222 held (−0%) | $11.13 | $6K | +20.2% |
| Dec 30SEC | CTNMContineum Therapeutics, Inc. | Sell Plan | 4,170164,392 held (−2%) | $12.23 | $51K | +9.4% |
- Sell
Chief Scientific Officer Daniel S. Lorrain sold $16K of CTNM at $16.00 — pre-scheduled 10b5-1 plan sale.
- Sell
Chief Scientific Officer Daniel S. Lorrain sold $400 of CTNM at $16.00 — pre-scheduled 10b5-1 plan sale.
- Sell
Chief Scientific Officer Daniel S. Lorrain sold $462K of CTNM at $16.04 — pre-scheduled 10b5-1 plan sale.
- Sell
Chief Scientific Officer Daniel S. Lorrain sold $92K of CTNM at $15.67 — pre-scheduled 10b5-1 plan sale.
- Sell
Chief Scientific Officer Daniel S. Lorrain sold $41K of CTNM at $16.24 — pre-scheduled 10b5-1 plan sale.
- Sell
Chief Scientific Officer Daniel S. Lorrain sold $55K of CTNM at $13.16 — pre-scheduled 10b5-1 plan sale.